| Features: |
| Erastin is often referred to as a "metabolic inhibitor" or a "ferroptosis inducer", rather than a traditional chemotherapy agent. Erastin is primarily available as a research chemical—it's not an approved therapeutic for clinical use. Pathways: -Erastin inhibits system xCT, thereby reducing cystine uptake. This leads to decreased intracellular cysteine, a precursor for GSH. As a consequence, the cell’s glutathione levels drop, compromising its ability to neutralize reactive oxygen species (ROS). -Glutathione (GSH) Depletion and Increased Oxidative Stress -Voltage-Dependent Anion Channels (VDACs): Altering VDAC function can affect mitochondrial metabolism, leading to changes in energy production and further enhancing oxidative stress. |
| Source: |
| Type: |
| Iron is an essential nutrient that is crucial for various cellular processes, including DNA synthesis, cell proliferation, and oxygen transport. Cancer cells often have increased iron requirements due to their rapid growth and proliferation. Some tumors can acquire iron through various mechanisms, including upregulating iron transport proteins. This can support their growth and survival. Excess iron can lead to the production of reactive oxygen species (ROS) through Fenton reactions, which can cause oxidative damage to DNA, proteins, and lipids. This oxidative stress can contribute to cancer development and progression. |
| 4892- | Sper, | erastin, | Spermidine inactivates proteasome activity and enhances ferroptosis in prostate cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vivo, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:241 Target#:160 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid